BIOX Bioceres Crop Solutions Corp. IFRS
Agricultural Chemicals · Nasdaq · SEC CIK 1769484 · Fiscal year ends 06/30
Financial factors as of 2025-12-31 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-28.4%
TTM net income YoY-16,023.8%
TTM EPS YoY-9,660.3%
Revenue 3-yr CAGR-10.3%
Net income 3-yr CAGR—
Margins
Gross margin39.1%
Operating margin0.8%
Net margin-83.4%
FCF margin27.7%
EBITDA margin—
Returns
ROE-123.8%
ROA-34.2%
ROIC (approx.)0.5%
Asset turnover0.41x
Leverage & solvency
Liabilities / assets81.0%
Debt / equity1.63x
Current ratio0.90x
Interest coverage0.07x
Cash quality & payout
Operating cash flow / net income-0.34x
Accruals ratio-46.0%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-06-30 | FY20242024-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $335.11M | $464.78M |
| Cost of revenue | $203.42M | $278.22M |
| Gross profit | $131.68M | $186.56M |
| R&D expense | $14.91M | $17.18M |
| SG&A expense | $123.11M | $123.69M |
| Operating income | -$2.24M | $45.85M |
| Interest expense | $28.84M | $26.87M |
| Pretax income | -$57.57M | $11.07M |
| Income tax | $1.27M | $3.78M |
| Net income | -$55.42M | $4.28M |
| EPS (basic) | -0.88 | 0.07 |
| EPS (diluted) | -0.88 | 0.07 |
| Weighted avg. shares (diluted) | 63.23M | 63.49M |
| Balance sheet | ||
| Cash & equivalents | $32.70M | $44.47M |
| Receivables | $165.86M | $207.32M |
| Inventory | $87.61M | $125.93M |
| Current assets | $308.31M | $408.67M |
| PP&E, netmay include right-of-use assets (IFRS) | $74.58M | $74.57M |
| Goodwill | $112.16M | $112.16M |
| Intangibles | $181.17M | $176.89M |
| Total assets | $763.65M | $852.55M |
| Current liabilities | $337.99M | $329.31M |
| Short-term debt | $119.73M | $136.75M |
| Long-term debt | $38.20M | $42.10M |
| Total debt | $157.93M | $178.85M |
| Total liabilities | $468.43M | $501.17M |
| Shareholders' equity | $265.44M | $315.04M |
| Net debt | $125.23M | $134.38M |
| Cash flow statement | ||
| Operating cash flow | $49.91M | $41.72M |
| Capital expenditure | $5.64M | $9.79M |
| Free cash flow | $44.26M | $31.93M |
| Investing cash flow | -$6.13M | -$28.73M |
| Financing cash flow | -$50.71M | -$10.06M |
| Stock-based compensation | $4.39M | $14.13M |
| Dividends paid | $72,051 | $174,800 |
| Share buybacks | $926,899 | $734,388 |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.